Jefferies Financial Group Weighs in on Pardes Biosciences, Inc.’s Q2 2022 Earnings (NASDAQ:PRDS)

Pardes Biosciences, Inc. (NASDAQ:PRDSGet Rating) – Investment analysts at Jefferies Financial Group dropped their Q2 2022 earnings per share estimates for Pardes Biosciences in a research note issued to investors on Tuesday, May 10th. Jefferies Financial Group analyst D. Ding now anticipates that the company will earn ($0.38) per share for the quarter, down from their previous forecast of ($0.33). Jefferies Financial Group has a “Buy” rating and a $25.00 price objective on the stock. Jefferies Financial Group also issued estimates for Pardes Biosciences’ Q3 2022 earnings at ($0.44) EPS, Q4 2022 earnings at ($0.52) EPS, FY2022 earnings at ($1.72) EPS, Q1 2023 earnings at ($0.61) EPS and Q2 2023 earnings at ($0.64) EPS.

Separately, SVB Leerink initiated coverage on shares of Pardes Biosciences in a research report on Tuesday, March 15th. They issued an “outperform” rating and a $18.00 price objective for the company.

Shares of Pardes Biosciences stock opened at $5.25 on Friday. The business’s fifty day simple moving average is $7.21. Pardes Biosciences has a twelve month low of $4.89 and a twelve month high of $17.76.

Large investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC purchased a new position in Pardes Biosciences in the 4th quarter valued at about $36,000. Penserra Capital Management LLC purchased a new position in Pardes Biosciences in the 4th quarter valued at about $54,000. Bank of New York Mellon Corp purchased a new position in Pardes Biosciences in the 1st quarter valued at about $75,000. Wells Fargo & Company MN bought a new position in shares of Pardes Biosciences during the fourth quarter worth about $315,000. Finally, D. E. Shaw & Co. Inc. bought a new position in shares of Pardes Biosciences during the fourth quarter worth about $623,000.

Pardes Biosciences Company Profile (Get Rating)

Pardes Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases.

Read More

Earnings History and Estimates for Pardes Biosciences (NASDAQ:PRDS)

Receive News & Ratings for Pardes Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pardes Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.